PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer’s Betaseron/Betaferon (IFNß-1b), Biogen’s Avonex (IFNß-1a) and Merck’s Rebif (IFNß-1a), and Teva’s Copaxone (glatiramer acetate), has been a salient feature of the MS therapeutics market. However, the competitive landscape is undergoing significant change with the emergence of oral therapies, several pipeline products with notable efficacies, and looming generics/biosimilars following the patent expiries of key branded products during the forecast period. In addition, the entry of new companies such as Sanofi/Genzyme and F. Hoffmann-La-Roche/Genentech will challenge the position of the established players in the MS marketplace.
The main driver of growth in this market is the launch of new MS DMTs, including oral agents that can be used as first-line therapy. Based on our primary research, French physicians are generally more receptive to products with novel mechanisms of action, which are likely to be priced higher than older drugs. In addition, with the high proportion of MS patients in France having a progressive MS subtype, the launch of new DMTs that specifically target SPMS and PPMS, such as masitinib and siponimod, will greatly increase treatment rates in these patients. France also has a lower-than-average rate of generic substitution compared with other countries, which will help off-patent drugs maintain their sales, although this may change during the forecast period due to government cost-cutting strategies.
Overview of the Multiple Sclerosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in France from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting France Multiple Sclerosis market.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Multiple Sclerosis
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in France